Table 14.
Post-hoc analysis: multi-variate model including an interaction between time period and being hospitalised for an injecting-related admission in the last 2 years among people prescribed OAT in all of Glasgow, 2010–2021 (June 2021 only)
| Co-variates | Na | HIV test in the last year (% of N) | Multi-variateb | |
|---|---|---|---|---|
| aOR (95% CI) | P value | |||
| Injecting-related hospital admission in the last 2 years—NO | ||||
| Time perioda | ||||
| Pre-outbreak (2010–2014) | 10,354 | 1,532 (15%) | 0.16 (0.15–0.17) | < 0.001 |
| Early outbreak (2015–2016) | 7,819 | 2,560 (33%) | 0.48 (0.45–0.51) | < 0.001 |
| Ongoing outbreak (2017–2019) | 7,359 | 3,613 (49%) | 1 | |
| COVID-19 (2020–2021) | 5,829 | 1,804 (31%) | 0.47 (0.44–0.51) | < 0.001 |
| Injecting-related hospital admission in the last 2 years—YES | ||||
| Pre-outbreak (2010–2014) | 1,554 | 411 (28%) | 2.37 (2.09–2.67) | < 0.001 |
| Early outbreak (2015–2016) | 1,700 | 870 (51%) | 2.19 (1.97–2.44) | < 0.001 |
| Ongoing outbreak (2017–2019) | 2,053 | 1440 (70%) | 2.44 (2.19–2.71) | < 0.001 |
| COVID-19 (2020–2021) | 1,770 | 1,043 (59%) | 3.15 (2.81–3.51) | < 0.001 |
| Local authority area | ||||
| Rest of Glasgow | 3,788 | 1,910 (50%) | 1 | |
| Glasgow city | 10,410 | 6,198 (59%) | 1.58 (1.49–1.68) | < 0.001 |
| Gender | ||||
| Male | 9,783 | 5,659 (58%) | 1 | |
| Female | 4,415 | 2,449 (55%) | 0.91 (0.86–0.97) | 0.002 |
| Age groupa | ||||
| < 35 | 6,738 | 2,312 (34%) | 1 | |
| 35–45 | 17,801 | 5,960 (35%) | 0.80 (0.75–0.86) | < 0.001 |
| 46 + | 14,619 | 5,031 (34%) | 0.61 (0.56–0.65) | 0.002 |
OR odds ratio, aOR adjusted odds ratio
aTime varying co-variate; people can be included in multiple categories
bMulti-level framework to adjust for across time period duplicates